Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For complete inclusion and exclusion, please refer to the investigator.
Competent to comprehend, sign, and date an Institutional Review Board (IRB) approved informed consent form
Subjects with advanced cancer in whom the gemcitabine and cisplatin chemotherapy regimen is clinically indicated
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate hematological function
Adequate renal function
Adequate hepatic function
Life expectancy of greater than or equal to 3 months as documented by the investigator
You may not be if
More than 1 prior chemotherapy regimen
History of venous thrombosis
Myocardial infarction, cerebrovascular accident, transient ischemic attack, percutaneous transluminal coronary angioplasty/stent, or unstable angina within 1 year before study enrollment
History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on screening chest computed tomograph (CT) scan
Average systolic blood pressure of greater than 145 mm Hg or average diastolic blood pressure of greater than 85 mm Hg
Radiotherapy within 28 days of study enrollment or within 14 days of study enrollment for peripheral lesions
Prior AMG 706, panitumumab, or another anti-EGFr monoclonal antibody (mAb) (e.g., cetuximab \[Erbitux®\] or EMD 72000)
Systemic chemotherapy within 28 days before study enrollment
Major surgery within 28 days or minor surgery within 14 days of study enrollment
Central nervous system metastases (Exception: subjects with treated asymptomatic central nervous system metastases, those who have been clinically stable in the judgment of the investigator and off steroids for at least 30 days before the study enrollment are eligible)
Clareo Health | Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer
